Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Position Boosted by Vestal Point Capital LP

Vestal Point Capital LP lifted its stake in shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH) by 172.2% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 1,075,000 shares of the company’s stock after purchasing an additional 680,000 shares during the period. Dianthus Therapeutics comprises about 1.4% of Vestal Point Capital LP’s investment portfolio, making the stock its 27th biggest holding. Vestal Point Capital LP’s holdings in Dianthus Therapeutics were worth $23,435,000 at the end of the most recent reporting period.

Several other large investors have also modified their holdings of DNTH. R Squared Ltd bought a new position in Dianthus Therapeutics in the fourth quarter worth about $26,000. KLP Kapitalforvaltning AS bought a new position in Dianthus Therapeutics in the fourth quarter worth about $33,000. KBC Group NV bought a new position in Dianthus Therapeutics in the fourth quarter worth about $35,000. BNP Paribas Financial Markets bought a new position in Dianthus Therapeutics in the fourth quarter worth about $59,000. Finally, AlphaQuest LLC lifted its holdings in Dianthus Therapeutics by 273.1% in the fourth quarter. AlphaQuest LLC now owns 4,197 shares of the company’s stock worth $91,000 after acquiring an additional 3,072 shares during the last quarter. Institutional investors own 47.53% of the company’s stock.

Dianthus Therapeutics Trading Up 5.0%

DNTH opened at $19.69 on Monday. The business’s 50 day moving average is $19.40 and its 200-day moving average is $22.07. The stock has a market cap of $633.23 million, a PE ratio of -7.88 and a beta of 1.48. Dianthus Therapeutics, Inc. has a twelve month low of $13.37 and a twelve month high of $32.27.

Dianthus Therapeutics (NASDAQ:DNTH) last posted its quarterly earnings data on Monday, May 12th. The company reported ($0.82) EPS for the quarter, beating analysts’ consensus estimates of ($0.86) by $0.04. Dianthus Therapeutics had a negative net margin of 1,250.32% and a negative return on equity of 21.68%. The business had revenue of $1.16 million for the quarter, compared to analyst estimates of $0.81 million. As a group, analysts forecast that Dianthus Therapeutics, Inc. will post -2.61 EPS for the current year.

Wall Street Analyst Weigh In

DNTH has been the topic of a number of recent research reports. Wedbush reissued an “outperform” rating and issued a $36.00 target price on shares of Dianthus Therapeutics in a report on Wednesday, March 12th. Robert W. Baird cut their target price on shares of Dianthus Therapeutics from $58.00 to $50.00 and set an “outperform” rating on the stock in a report on Tuesday, May 13th. HC Wainwright reissued a “buy” rating and issued a $40.00 target price on shares of Dianthus Therapeutics in a report on Tuesday, May 13th. Finally, Guggenheim reaffirmed a “buy” rating and set a $84.00 price target on shares of Dianthus Therapeutics in a report on Wednesday, March 12th. Seven research analysts have rated the stock with a buy rating and two have given a strong buy rating to the stock. According to MarketBeat.com, Dianthus Therapeutics currently has an average rating of “Buy” and an average target price of $53.00.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.